APA (7th ed.) Citation

K, S., YJ, B., LS, W., SY, R., T, O., F, P., . . . SE, A. (2026). Surrogate endpoints for survival in KEYNOTE-585: Neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma. ESMO open, 11(3), 106090. https://doi.org/10.1016/j.esmoop.2026.106090

Chicago Style (17th ed.) Citation

K, Shitara, et al. "Surrogate Endpoints for Survival in KEYNOTE-585: Neoadjuvant/adjuvant Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma." ESMO Open 11, no. 3 (2026): 106090. https://doi.org/10.1016/j.esmoop.2026.106090.

MLA (9th ed.) Citation

K, Shitara, et al. "Surrogate Endpoints for Survival in KEYNOTE-585: Neoadjuvant/adjuvant Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma." ESMO Open, vol. 11, no. 3, 2026, p. 106090, https://doi.org/10.1016/j.esmoop.2026.106090.